2024
JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Sarkaria J, Mrugala M, Jaeckle K, Burns T, Vaubel R, Parney I, Chaichana K, Clement P, Martínez-García M, Sanchez J, Omuro A, Pronk L, Ross H, Teufel M, Hesse R, Grempler R, Galanis E. JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2024, 26: v13-v13. PMCID: PMC11485993, DOI: 10.1093/neuonc/noae144.036.Peer-Reviewed Original ResearchNon-contrast-enhancedMouse double minute 2Contrast enhancementMGMT promoter unmethylated glioblastomaPatient-derived xenograft modelsUnbound concentrationsCalculated unbound concentrationsNewly diagnosed GBMMaximum tolerated doseNewly diagnosed glioblastomaTumor cell apoptosisSingle-arm trialMDM2-p53 antagonistsDouble minute 2Restore wild-typeBrain tissueBrain tumor tissueTP53 WTUnmethylated glioblastomaPhase 0Diagnosed glioblastomaTolerated doseOpen-labelP53 target gene expressionIDH-wtA phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Sarkaria J, Mrugala M, Jaeckle K, Burns T, Vaubel R, Parney I, Chaichana K, Clement P, Martinez-Garcia M, Sepulveda Sanchez J, Omuro A, Pronk L, Ross H, Teufel M, Hesse R, Grempler R, Galanis E. A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM). Journal Of Clinical Oncology 2024, 42: 2017-2017. DOI: 10.1200/jco.2024.42.16_suppl.2017.Peer-Reviewed Original ResearchNon-contrast-enhancedOpen-labelContrast enhancementMGMT promoter unmethylated glioblastomaUnbound concentrationsCalculated unbound concentrationsNewly diagnosed GBMDose-escalation studyMaximum tolerated doseTumor cell apoptosisSingle-arm trialMDM2-p53 antagonistsRestore wild-typeBrain tissueUnmethylated glioblastomaBrain tumor tissueEscalation studyDiagnosed glioblastomaTolerated doseP53 target gene expressionPrimary endpointIDH-wtSolid tumorsTumor tissuesXenograft model
2013
An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC) (IN10-2.005)
Nayak L, Abrey L, DeAngelis L, Gadgeel S, Garst J, Govindan R, Kelly K, Omuro A, Peereboom D, Ramnath N, Reimers H, Rigas J, Robbins H, Rosenfeld S, Wen P. An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC) (IN10-2.005). Neurology 2013, 80 DOI: 10.1212/wnl.80.7_supplement.in10-2.005.Peer-Reviewed Original ResearchAn Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC) (S56.002)
Nayak L, Abrey L, DeAngelis L, Gadgeel S, Garst J, Govindan R, Kelly K, Omuro A, Peereboom D, Ramnath N, Reimers H, Rigas J, Robbins H, Rosenfeld S, Wen P. An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC) (S56.002). Neurology 2013, 80 DOI: 10.1212/wnl.80.7_supplement.s56.002.Peer-Reviewed Original Research